Biogen Buys Apellis for $5.6B to Expand Kidney Drugs

Bloomberg's Michelle Davis joins Dani Burger on Bloomberg Deals. Biogen has agreed to acquire Apellis Pharmaceuticals for 5.6 billion, expanding its treatments in immunology and rare diseases in one of the company’s largest-ever acquisitions. (Source: Bloomberg)